Autopsy report · NCT00453193
Alemtuzumab and Pentostatin In T-cell Neoplasms
Cause of deathSlow enrollment
“Slow accrual.”
Life of this trial
- Registered 2 years 6 months after it had already started.
- Ran for about 5 years 6 months before it stopped.
- 26 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Lymphoma; Leukemia
- Interventions
- Pentostatin; Alemtuzumab
- Participants
- 26
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.